These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 30068939)
1. Hippo signaling dysfunction induces cancer cell addiction to YAP. Han H; Yang B; Nakaoka HJ; Yang J; Zhao Y; Le Nguyen K; Bishara AT; Mandalia TK; Wang W Oncogene; 2018 Dec; 37(50):6414-6424. PubMed ID: 30068939 [TBL] [Abstract][Full Text] [Related]
3. Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Ma Y; Yang Y; Wang F; Wei Q; Qin H Int J Cancer; 2015 Nov; 137(10):2275-86. PubMed ID: 25042563 [TBL] [Abstract][Full Text] [Related]
4. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway. Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277 [TBL] [Abstract][Full Text] [Related]
5. Targeting YAP and Hippo signaling pathway in liver cancer. Liu AM; Xu MZ; Chen J; Poon RT; Luk JM Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481 [TBL] [Abstract][Full Text] [Related]
6. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Mo JS; Meng Z; Kim YC; Park HW; Hansen CG; Kim S; Lim DS; Guan KL Nat Cell Biol; 2015 Apr; 17(4):500-10. PubMed ID: 25751140 [TBL] [Abstract][Full Text] [Related]
7. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Lin L; Sabnis AJ; Chan E; Olivas V; Cade L; Pazarentzos E; Asthana S; Neel D; Yan JJ; Lu X; Pham L; Wang MM; Karachaliou N; Cao MG; Manzano JL; Ramirez JL; Torres JM; Buttitta F; Rudin CM; Collisson EA; Algazi A; Robinson E; Osman I; Muñoz-Couselo E; Cortes J; Frederick DT; Cooper ZA; McMahon M; Marchetti A; Rosell R; Flaherty KT; Wargo JA; Bivona TG Nat Genet; 2015 Mar; 47(3):250-6. PubMed ID: 25665005 [TBL] [Abstract][Full Text] [Related]
8. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Chen M; Wang M; Xu S; Guo X; Jiang J Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204 [TBL] [Abstract][Full Text] [Related]
9. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway. Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643 [TBL] [Abstract][Full Text] [Related]
10. Regulation of YAP by mechanical strain through Jnk and Hippo signaling. Codelia VA; Sun G; Irvine KD Curr Biol; 2014 Sep; 24(17):2012-7. PubMed ID: 25127217 [TBL] [Abstract][Full Text] [Related]
11. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099 [TBL] [Abstract][Full Text] [Related]
12. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung. Lange AW; Sridharan A; Xu Y; Stripp BR; Perl AK; Whitsett JA J Mol Cell Biol; 2015 Feb; 7(1):35-47. PubMed ID: 25480985 [TBL] [Abstract][Full Text] [Related]
13. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1. Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671 [TBL] [Abstract][Full Text] [Related]
14. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Zhang L; Yang S; Chen X; Stauffer S; Yu F; Lele SM; Fu K; Datta K; Palermo N; Chen Y; Dong J Mol Cell Biol; 2015 Apr; 35(8):1350-62. PubMed ID: 25645929 [TBL] [Abstract][Full Text] [Related]
15. Hippo-yap signaling in ocular development and disease. Lee M; Goraya N; Kim S; Cho SH Dev Dyn; 2018 Jun; 247(6):794-806. PubMed ID: 29532607 [TBL] [Abstract][Full Text] [Related]
16. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3. Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596 [TBL] [Abstract][Full Text] [Related]
17. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma. Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036 [TBL] [Abstract][Full Text] [Related]
18. The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes. Wennmann DO; Vollenbröker B; Eckart AK; Bonse J; Erdmann F; Wolters DA; Schenk LK; Schulze U; Kremerskothen J; Weide T; Pavenstädt H Cell Death Dis; 2014 Nov; 5(11):e1519. PubMed ID: 25393475 [TBL] [Abstract][Full Text] [Related]
19. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750 [TBL] [Abstract][Full Text] [Related]